Becton, Dickinson and Company (BD) is an American medical technology company that manufactures and sells medical devices, instrument systems, and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 50,000 people in more than 50 countries throughout the world. In fiscal year ending September 30, 2009, 60% of BD sales were generated from non-U.S. markets.
The company’s customers include health care institutions, science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD was one of the first companies to sell U.S.-made glass syringes. It was also a pioneer in the production of hypodermic needles. Today, BD is divided into two segments: BD Medical and BD Life Sciences.[3] BD is ranked #225 in the 2017 Fortune 500 list.
The firm in October 2014 agreed to acquire CareFusion for a price of $12.2 billion in cash and stock. In April 2017 Becton Dickinson agreed to acquire C. R. Bard for $24 billion.
Maher Elhassan, Beckton Dickinson’s VP and general manager for the Middle East, North Africa, and Turkey (MENAT), comments on the company’s important role during the COVID-19 pandemic – including the…
On Becton Dickinson’s 40th anniversary in Spain, Lourdes López Jiménez, general manager of BD Spain & Portugal, introduces BD’s strong manufacturing footprint in the country and emphasizes the importance of…
Łukasz Korybalski, regional manager of Becton Dickinson (BD) Central Eastern Europe, discusses the rising significance of the region as the company continues to grow and the strategic importance of Poland,…
BD Mexico was the 2nd subsidiary ever opened abroad by BD worldwide – after Canada – and that was as early as 1957. Can you explain the very early focus…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
BD’s Loay Badr outlines the rationale behind the medtech giant’s recent establishment of a direct presence in Egypt, the significant opportunities for medical device players in the country as it…
The Saudi medtech market was valued at USD 2.25 billion in 2017 and is expected to reach USD 3.87 billion at a CAGR of 9.5 percent by 2023, according to…
Maher Elhassan, Beckton Dickinson’s VP and general manager for the Middle East, North Africa, and Turkey (MENAT), comments on the company’s important role during the COVID-19 pandemic – including the…
With four manufacturing plants in three sites, Becton, Dickinson and Company is a symbol of the Puerto Rico’s manufacturing prowess. José Sánchez, director of Reagent Manufacturing and operations manager for…
BD Mexico was the 2nd subsidiary ever opened abroad by BD worldwide – after Canada – and that was as early as 1957. Can you explain the very early focus…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
See our Cookie Privacy Policy Here
